Katharina A. Mayer

990 total citations
28 papers, 644 citations indexed

About

Katharina A. Mayer is a scholar working on Transplantation, Immunology and Surgery. According to data from OpenAlex, Katharina A. Mayer has authored 28 papers receiving a total of 644 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Transplantation, 10 papers in Immunology and 7 papers in Surgery. Recurrent topics in Katharina A. Mayer's work include Renal Transplantation Outcomes and Treatments (21 papers), Immune Cell Function and Interaction (8 papers) and Renal Diseases and Glomerulopathies (7 papers). Katharina A. Mayer is often cited by papers focused on Renal Transplantation Outcomes and Treatments (21 papers), Immune Cell Function and Interaction (8 papers) and Renal Diseases and Glomerulopathies (7 papers). Katharina A. Mayer collaborates with scholars based in Austria, Germany and Switzerland. Katharina A. Mayer's co-authors include Guido A. Gualdoni, Gerhard J. Zlabinger, Johannes Stöckl, Georg A. Böhmig, Konstantin Doberer, Lisa Göschl, Nicole Boucheron, Wilfried Ellmeier, Farsad Eskandary and Philip F. Halloran and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and The FASEB Journal.

In The Last Decade

Katharina A. Mayer

27 papers receiving 639 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Katharina A. Mayer Austria 13 228 218 142 130 106 28 644
Karen S. Keslar United States 13 108 0.5× 211 1.0× 111 0.8× 190 1.5× 67 0.6× 25 591
Marleen Seiler Germany 6 138 0.6× 116 0.5× 116 0.8× 128 1.0× 153 1.4× 6 579
Keith Zucker United States 13 372 1.6× 113 0.5× 159 1.1× 144 1.1× 262 2.5× 23 817
B. Suárez Spain 14 53 0.2× 360 1.7× 66 0.5× 65 0.5× 194 1.8× 25 626
S. Agrawal India 17 59 0.3× 572 2.6× 72 0.5× 94 0.7× 89 0.8× 46 957
Philippe Pouletty United States 15 265 1.2× 260 1.2× 168 1.2× 147 1.1× 52 0.5× 37 664
Noureddine Berka Canada 10 58 0.3× 187 0.9× 58 0.4× 38 0.3× 148 1.4× 60 429
Morten Buus Jørgensen Denmark 13 28 0.1× 152 0.7× 171 1.2× 229 1.8× 77 0.7× 29 616
Paul Risley United Kingdom 13 19 0.1× 245 1.1× 129 0.9× 110 0.8× 208 2.0× 15 654
Timi Martelius Finland 13 51 0.2× 191 0.9× 147 1.0× 69 0.5× 200 1.9× 37 577

Countries citing papers authored by Katharina A. Mayer

Since Specialization
Citations

This map shows the geographic impact of Katharina A. Mayer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katharina A. Mayer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katharina A. Mayer more than expected).

Fields of papers citing papers by Katharina A. Mayer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katharina A. Mayer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katharina A. Mayer. The network helps show where Katharina A. Mayer may publish in the future.

Co-authorship network of co-authors of Katharina A. Mayer

This figure shows the co-authorship network connecting the top 25 collaborators of Katharina A. Mayer. A scholar is included among the top collaborators of Katharina A. Mayer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katharina A. Mayer. Katharina A. Mayer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Diebold, Matthias, P. Gauthier, Katharina A. Mayer, et al.. (2025). Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies. Nature Medicine. 31(5). 1668–1676. 7 indexed citations
2.
Mayer, Katharina A., et al.. (2025). CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluation. Expert Opinion on Investigational Drugs. 34(1-2). 1–10. 3 indexed citations
3.
Mayer, Katharina A., et al.. (2025). Targeting CD38 in Antibody-Mediated Rejection. Transplant International. 38. 14343–14343.
4.
Mayer, Katharina A., et al.. (2024). Chronic Rejection After Kidney Transplantation. Transplantation. 109(4). 610–621. 9 indexed citations
5.
Diebold, Matthias, Hannes Vietzen, Andreas Heinzel, et al.. (2023). Natural killer cell functional genetics and donor-specific antibody-triggered microvascular inflammation. American Journal of Transplantation. 24(5). 743–754. 15 indexed citations
6.
Herz, Carsten T., Matthias Diebold, Alexander Kainz, et al.. (2023). Morphologic and Molecular Features of Antibody-Mediated Transplant Rejection: Pivotal Role of Molecular Injury as an Independent Predictor of Renal Allograft Functional Decline. Transplant International. 36. 12135–12135. 5 indexed citations
7.
Mayer, Katharina A., Konstantin Doberer, Philip F. Halloran, et al.. (2022). Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Kidney Transplant Rejection: Effect on Donor-derived Cell-free DNA and C-X-C Motif Chemokine Ligand 10. Transplantation Direct. 8(12). e1406–e1406. 8 indexed citations
8.
Mayer, Katharina A., Klemens Budde, Philip F. Halloran, et al.. (2022). Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial. Trials. 23(1). 270–270. 15 indexed citations
9.
Kainz, Alexander, Nicolas Kozakowski, Heinz Regele, et al.. (2022). Early Estimated Glomerular Filtration Rate Trajectories After Kidney Transplant Biopsy as a Surrogate Endpoint for Graft Survival in Late Antibody-Mediated Rejection. Frontiers in Medicine. 9. 817127–817127. 5 indexed citations
10.
Vietzen, Hannes, Bernd Döhler, Thuong Hien Tran, et al.. (2022). Deletion of the Natural Killer Cell Receptor NKG2C Encoding KLR2C Gene and Kidney Transplant Outcome. Frontiers in Immunology. 13. 829228–829228. 17 indexed citations
11.
Mayer, Katharina A., Ursula Smole, Sophia Derdak, et al.. (2021). The energy sensor AMPK orchestrates metabolic and translational adaptation in expanding T helper cells. The FASEB Journal. 35(4). e21217–e21217. 14 indexed citations
12.
Mayer, Katharina A., Konstantin Doberer, Susanne Haindl, et al.. (2021). Diagnostic value of donor‐derived cell‐free DNA to predict antibody‐mediated rejection in donor‐specific antibody‐positive renal allograft recipients. Transplant International. 34(9). 1689–1702. 30 indexed citations
13.
Mühlbacher, Jakob, Christian Schörgenhofer, Konstantin Doberer, et al.. (2021). Anti‐interleukin‐6 antibody clazakizumab in late antibody‐mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism. Transplant International. 34(8). 1542–1552. 7 indexed citations
14.
Reiter, Thomas, Ludwig Wagner, Martina Gaggl, et al.. (2021). COVID-19 serology in nephrology healthcare workers. Wiener klinische Wochenschrift. 133(17-18). 923–930. 5 indexed citations
15.
Wahrmann, Markus, Bernd Döhler, Marie-Luise Arnold, et al.. (2021). Functional Fc Gamma Receptor Gene Polymorphisms and Long-Term Kidney Allograft Survival. Frontiers in Immunology. 12. 724331–724331. 7 indexed citations
16.
Bustamante, Gabriela, et al.. (2020). Cesarean section and risk of allergies in Ecuadorian children: A cross‐sectional study. Immunity Inflammation and Disease. 8(4). 763–773. 12 indexed citations
17.
Mayer, Katharina A., Konstantin Doberer, Farsad Eskandary, Philip F. Halloran, & Georg A. Böhmig. (2020). New concepts in chronic antibody-mediated kidney allograft rejection: prevention and treatment. Current Opinion in Organ Transplantation. 26(1). 97–105. 14 indexed citations
18.
Doberer, Konstantin, Johannes Kläger, Guido A. Gualdoni, et al.. (2020). CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection. Transplantation. 105(2). 451–457. 71 indexed citations
19.
Mayer, Katharina A., Johannes Stöckl, Gerhard J. Zlabinger, & Guido A. Gualdoni. (2019). Hijacking the Supplies: Metabolism as a Novel Facet of Virus-Host Interaction. Frontiers in Immunology. 10. 1533–1533. 130 indexed citations
20.
Gualdoni, Guido A., Katharina A. Mayer, Philip Kienzl, et al.. (2018). Rhinovirus induces an anabolic reprogramming in host cell metabolism essential for viral replication. Proceedings of the National Academy of Sciences. 115(30). E7158–E7165. 108 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karen S. Keslar Breakdown of academic impact, for papers by Marleen Seiler Breakdown of academic impact, for papers by Keith Zucker Breakdown of academic impact, for papers by B. Suárez Breakdown of academic impact, for papers by S. Agrawal Breakdown of academic impact, for papers by Philippe Pouletty Breakdown of academic impact, for papers by Noureddine Berka Breakdown of academic impact, for papers by Morten Buus Jørgensen Breakdown of academic impact, for papers by Paul Risley Breakdown of academic impact, for papers by Timi Martelius
Rankless by CCL
2026